Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye.
$7.64+1.87%
报价 2026-11-13
市值
$471.6M
EV
–
PE (TTM)
–
预期 PE
–
52 周区间距高点 -76.6%
$6.83$32.65
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| OCSOculis Holding AG | $471.6M | +1.9% | – | -2,889.4% | – | – | – | |
| PHATPhathom Pharmaceuticals, Inc. | $492.6M | -2.7% | +80.5% | 80.7% | – | – | – | |
| MNPRMonopar Therapeutics Inc. | $487.9M | -0.9% | – | 0% | – | – | – | |
| CADLCandel Therapeutics, Inc. | $486.4M | -26.1% | +2051.2% | 0% | – | – | – | |
| OVIDOvid Therapeutics Inc. | $479.4M | -0.4% | -87.9% | 100% | – | – | – | |
| DMACDiaMedica Therapeutics Inc. | $474.3M | -5.8% | +10700.0% | 0% | – | – | – | |
| STTKShattuck Labs, Inc. | $473.6M | -3.3% | -91.7% | -82% | – | – | – | |
| GYREGyre Therapeutics, Inc. | $471.7M | +0.2% | -1.9% | 94.2% | – | – | – | |
| MDXGMiMedx Group, Inc. | $468.4M | -0.9% | -37.2% | 82.6% | 12.9x | 6.0x | 23.0x | |
| 同行中位数 | – | – | -1.9% | 40.3% | 12.9x | 6.0x | 23.0x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
报告货币 CHF(非美元)暂无季度数据(首次研究运行后填充)。